Citius Oncology Inc.

XNAS:CTOR 4:00:00 PM EDT

1.15

-0.05 (-4.17%)

7:59:18 PM EDT: $1.18 +0.03 (+2.61%)

Market Cap (Intraday)	97.51M
Current PE	N/A
Forward PE	N/A
2yr Forward PE	1.72

See more stats

Estimates Current Quarter

Revenue	$4.37 Million
Adjusted EPS	-$0.04

See more estimates

10-Day MA	$1.13
50-Day MA	$1.30
200-Day MA	$1.56

See more pivots

Citius Oncology Inc. Stock, XNAS:CTOR

11 Commerce Drive, 1st floor, Cranford, New Jersey 07016

United States of America

Phone:

Number of Employees:

Description

Citius Oncology, Inc. is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.